Search results
- 2.4301Add to watchlist+0.0201 (+0.82%)As of Tue. Jun 4, 2024 9:34 AM EDT · Nasdaq Real Time Price (USD) · Market open
- Open2.4500High2.4799Low2.4201
- Mkt Cap20.96MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close2.410052 Wk. Low1.020052 Wk. High17.6000
Related stocks
A high-level overview of iBio, Inc. (IBIO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
May 21, 2024 · Nasdaq. 16,832.63. +0.22% US 10 Yr. 4.45. –0.25% FTSE 100. 8,393.23. –0.28% Crude Oil. 78.29. –0.47% Gold. 2,442.40. –0.27% Euro. 1.08. –0.16% Pound/Dollar. 1.27. +0.10% Markets. Data. iBio Inc....
6 days ago · iBio (IBIO) Stock Price, News & Analysis. → Biden replacement revealed? (From Paradigm Press) Free IBIO Stock Alerts. $2.47. +0.08 (+3.35%) (As of 05/29/2024 ET) Compare. Share. Today's Range. $2.27. . $2.58. 50-Day Range. N/A. 52-Week Range. $1.02. . $17.60. Volume. 255,231 shs. Average Volume. 2.41 million shs. Market Capitalization.
May 24, 2024 · See the latest iBio Inc stock price (IBIO:XASE), related news, valuation, dividends and more to help you make your investing decisions.
3 days ago · +0.150 (6.73%) May 31, 2024, 4:00 PM EDT - Market closed. Overview. Financials. Statistics. Forecast. Profile. Chart. Company Description. iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.
5 days ago · iBio, Inc. Stock. Equities. IBIO. US4510337086. Pharmaceuticals. Summary. Quotes. Charts. News. Calendar. Company. Financials. Consensus. Revisions. Funds and ETFs. Financials (USD) More Fundamentals * Assessed data. Chart iBio, Inc. Duration. Period. Style. Dynamic Chart. Latest news about iBio, Inc. More news. Latest transcript on iBio, Inc.
May 24, 2024 · iBio, Inc. Stock Forecast. All Analysts. Top Analysts. Stock Price Forecast. The 1 analyst with a 12-month price forecast for iBio, Inc. stock has a target of 5.00, which predicts an increase of 128.31% from the current stock price of 2.19. Analyst Consensus: Strong Buy. Analyst Ratings.